Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 7.5% – What’s Next?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s stock price fell 7.5% during trading on Friday . The stock traded as low as $33.06 and last traded at $33.22. 99,557 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 1,016,120 shares. The stock had previously closed at $35.90.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Raymond James reissued an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada raised their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Trading Down 4.1 %

The company has a market cap of $1.96 billion, a PE ratio of 3.03 and a beta of 0.87. The firm has a fifty day moving average of $46.56 and a two-hundred day moving average of $45.43.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Erste Asset Management GmbH purchased a new position in Agios Pharmaceuticals during the third quarter valued at approximately $97,199,000. Marshall Wace LLP grew its position in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after purchasing an additional 855,739 shares in the last quarter. Vestal Point Capital LP bought a new position in shares of Agios Pharmaceuticals in the third quarter worth $33,767,000. Frazier Life Sciences Management L.P. raised its position in shares of Agios Pharmaceuticals by 66.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock worth $37,600,000 after buying an additional 348,808 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in Agios Pharmaceuticals by 87.3% during the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock valued at $29,245,000 after buying an additional 316,100 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.